COVID-19. U07.1 COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: In the intervention group, hospitalized patients with Covid 19, in addition to standard treatment (Remdesivier, and glucocorticoids such as dexamethasone, methylpre
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Hospitalized patients with definitive diagnosis of Covid 19 using PCR or CT scan Conscious consent to participate in the study Age category 18 years and above
Exclusion criteria
Exclusion criteria: Acute pancreatitis Pregnancy and lactation Having autoimmune diseases and taking immunosuppressants or drugs used to reject transplants Taking supplements containing probiotics and prebiotics in the last three months Hospitalization in the ICU Patients treated with herbal medicines or other traditional medicine methods Dialysis patients Having a history of allergies to synbiotics Dissatisfaction with participating in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The level of CRP inflammatory marker. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.;The level of IL-6 inflammatory cytokine. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: ELISA.;ESR level. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT level. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.;AST level. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.;ALP level. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.;Creatinine level. Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.;Complete Blood Count (CBC). Timepoint: At the beginning of the study and fourteen days after taking the capsule. Method of measurement: Blood test.;Cough. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Fever. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Breathing rate. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up (number of breaths per minute).;Sore throat. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Generalized body pain. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Dyspnea. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;SPO2. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Weakness and lethargy. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Stomach pain. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Chest pain. Timepoint: Daily (first day to fourteenth day of intervention). Method of measurement: Clinical check up.;Gastrointestinal symptoms (diarrhea, vomiting and nausea). Timepoint: Daily (first day to fourteenth | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMona Kabiri
Mashhad University of Medical Sciences
Outcome results
None listed